Cargando…
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression. In this study, we employed bispecific antibody approach to target Muc1 positive tumor cells. A novel bispecific antib...
Autores principales: | Li, Yumei, Zhou, Changhua, Li, Jing, Liu, Jiayu, Lin, Limin, Li, Li, Cao, Donglin, Li, Qing, Wang, Zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777659/ https://www.ncbi.nlm.nih.gov/pubmed/29357376 http://dx.doi.org/10.1371/journal.pone.0191024 |
Ejemplares similares
-
Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
por: Fang, Jun, et al.
Publicado: (2023) -
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
por: Li, Zhaoyi, et al.
Publicado: (2019) -
MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
por: Betge, Johannes, et al.
Publicado: (2016) -
Expression of MUC1 and MUC4 in Gallbladder Adenocarcinoma
por: Kim, Su-Mi, et al.
Publicado: (2012) -
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)
por: Hanson, Ryan L., et al.
Publicado: (2016)